Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingelise Gordon

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Contemporary Clinical Trials|May 1, 2012
Randomization to standard and concise informed consent forms: development of evidence-based consent practicesMary E Enama, Zonghui Hu, Ingelise Gordon, et al.
Research Square|December 31, 2025
Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody ResponsesKizzmekia Corbett-Helaire, Christian Dzuvor, Sydney Moak, et al.
Contemporary Clinical Trials|August 16, 2015
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boostJulie E Ledgerwood, Zonghui Hu, Pamela Costner, et al.
British Journal of Haematology|September 21, 2022
Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemiaRoma V Rajput, Xiaoyang Ma, Kristin L Boswell, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
Science Translational Medicine|April 19, 2023
An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humansSarah F Andrews, Lauren Y Cominsky, Geoffrey D Shimberg, et al.
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron NeutralizationNicole A Doria-Rose, Xiaoying Shen, Stephen D Schmidt, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials|May 1, 2012
Randomization to standard and concise informed consent forms: development of evidence-based consent practicesMary E Enama, Zonghui Hu, Ingelise Gordon, et al.
Research Square|December 31, 2025
Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody ResponsesKizzmekia Corbett-Helaire, Christian Dzuvor, Sydney Moak, et al.
Contemporary Clinical Trials|August 16, 2015
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boostJulie E Ledgerwood, Zonghui Hu, Pamela Costner, et al.
British Journal of Haematology|September 21, 2022
Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemiaRoma V Rajput, Xiaoyang Ma, Kristin L Boswell, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
Science Translational Medicine|April 19, 2023
An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humansSarah F Andrews, Lauren Y Cominsky, Geoffrey D Shimberg, et al.
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Medrxiv : the Preprint Server for Health Sciences|December 21, 2021
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron NeutralizationNicole A Doria-Rose, Xiaoying Shen, Stephen D Schmidt, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
Pageof 2